title: The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors.
abstract: Identifying factors that influence gene transfer efficacy is critical for a successful gene-based clinical study. Here we demonstrate that in vivo AAV-2-mediated gene transfer is efficiently inhibited by unfractionated heparin, but not by a heparin preparation containing mainly low-molecular-weight forms (LMWH). Surprisingly, inhibitors of thrombin or factor Xa (F.Xa) significantly reduced AAV-2 transduction in a dose-dependent manner. These effects were independent of the vector promoter, transgene, or strain of mice. Expression by alternate AAV serotypes 5 and 8 was not affected by anticoagulant drugs, which suggests an AAV-2-specific effect. Moreover, AAV-2-mediated gene expression was diminished in mice with deficiency in thrombin generation (factor IX deficiency) and enhanced in mice with procoagulant phenotype due to factor V Leiden. In addition, inhibitors of F.Xa diminished adenovirus-mediated gene expression. These results demonstrated that coagulation activity itself is critical to ensure optimal viral vector transduction. Since intravascular delivery of vectors often requires the use of anticoagulants, the use of LMWH appears to be safe. These observations are of relevance for approaches using AAV-2 or adenoviral vectors, especially in early phase studies designed to identify the minimum therapeutic doses.
authors.affiliation: Department of Pediatrics, University of Pennsylvania Medical Center and The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
authors.forename: Joerg
authors.initials: J
authors.lastname: Schuettrumpf
authors.forename: Jianxiang
authors.initials: J
authors.lastname: Zou
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Alexander
authors.initials: A
authors.lastname: Schlachterman
authors.forename: Yi-Lin
authors.initials: YL
authors.lastname: Liu
authors.forename: Shyrie
authors.initials: S
authors.lastname: Edmonson
authors.forename: Weidong
authors.initials: W
authors.lastname: Xiao
authors.forename: Valder R
authors.initials: VR
authors.lastname: Arruda
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D060829:Arthropod Proteins; D001778:Blood Coagulation Disorders / Q000235:genetics / Q000628:therapy; D002460:Cell Line; D000229:Dependovirus / Q000235:genetics*; D005165:Factor V / Q000235:genetics / Q000378:metabolism; D065427:Factor Xa Inhibitors; D018628:Gene Dosage / Q000187:drug effects; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D006493:Heparin / Q000494:pharmacology; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010455:Peptides / Q000494:pharmacology; D013045:Species Specificity; D013917:Thrombin / Q000037:antagonists & inhibitors; D014161:Transduction, Genetic
chemical_list: D000925:Anticoagulants; D060829:Arthropod Proteins; D065427:Factor Xa Inhibitors; D006629:Hirudins; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C095381:factor V Leiden; C063967:tick anticoagulant peptide; D005165:Factor V; D006493:Heparin; D013917:Thrombin